Publicacións nas que colabora con María Angeles Moro Sánchez (21)

2013

  1. Neuronal excitotoxicity after carotid angioplasty and stent placement procedures

    Radiology, Vol. 268, Núm. 2, pp. 515-520

2011

  1. The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome

    Thrombosis and Haemostasis, Vol. 105, Núm. 3, pp. 421-429

2008

  1. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke

    Neurobiology of Disease, Vol. 29, Núm. 1, pp. 123-131

2007

  1. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke

    Neurobiology of Disease, Vol. 26, Núm. 1, pp. 105-111

  2. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke

    Stroke, Vol. 38, Núm. 1, pp. 90-95

  3. Statin treatment withdrawal in ischemic stroke: A controlled randomized study

    Neurology, Vol. 69, Núm. 9, pp. 904-910

  4. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome

    Stroke, Vol. 38, Núm. 10, pp. 2759-2764

2006

  1. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke

    Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717

  2. Neurorepair versus neuroprotection in stroke

    Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 54-63

  3. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms

    Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229

  4. Targets of cytoprotection in acute ischemic stroke: Present and future

    Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 1-8

2005

  1. Increased plasma levels of 15-deoxy Δ prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke

    Stroke, Vol. 36, Núm. 6, pp. 1189-1194

  2. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia

    Neurobiology of Disease, Vol. 18, Núm. 2, pp. 375-384

  3. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: Effects on glutamate transport

    Neurobiology of Disease, Vol. 18, Núm. 2, pp. 336-345

  4. TNFR1 upregulation mediates tolerance after brain ischemic preconditioning

    Journal of Cerebral Blood Flow and Metabolism, Vol. 25, Núm. 2, pp. 193-203

  5. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers

    Stroke, Vol. 36, Núm. 9, pp. 1921-1926

2003

  1. L-arginine levels in blood as a marker of nitric oxide-mediated brain damage in acute stroke: A clinical and experimental study

    Journal of Cerebral Blood Flow and Metabolism, Vol. 23, Núm. 8, pp. 978-984

  2. Neuroprotective effects of aspirin in patients with acute cerebral infarction

    Neuroscience Letters, Vol. 339, Núm. 3, pp. 248-250

  3. The Release of Tumor Necrosis Factor-α is Associated with Ischemic Tolerance in Human Stroke

    Annals of Neurology, Vol. 54, Núm. 6, pp. 811-819

2002

  1. Upregulation of TACE/ADAM17 after ischemic preconditioning is involved in brain tolerance

    Journal of Cerebral Blood Flow and Metabolism, Vol. 22, Núm. 11, pp. 1297-1302